Coherus BioSciences

$16.13
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.30 (+1.90%) As of 7:31 PM UTC today

Why Robinhood?

You can buy or sell CHRS and other stocks, options, and ETFs commission-free!

About CHRS

Coherus BioSciences, Inc. Common Stock, also called Coherus BioSciences, is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA. The listed name for CHRS is Coherus BioSciences, Inc. Common Stock.

CEO
Denny M. Lanfear
Employees
317
Headquarters
Redwood City, California
Founded
2010
Market Cap
1.19B
Price-Earnings Ratio
9.75
Dividend Yield
—
Average Volume
1.96M
High Today
$16.48
Low Today
$15.88
Open Price
$15.94
Volume
869.56K
52 Week High
$22.22
52 Week Low
$10.86

CHRS Earnings

$0.08
$0.32
$0.57
$0.81
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
$0.23 per share
Actual
$0.23 per share
Replay Earnings Call

You May Also Like

GLD
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure